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Abstract
It is still common practice to correct abnormal standard laboratory test results, such as increased INR or low platelet
count, prior to invasive interventions, such as tracheostomy, central venous catheter insertion or liver biopsy, in
critically ill patients. Data suggest that 30–90 % of plasma transfused for these indications is unnecessary and puts
the patient at risk. Plasma transfusion is associated with a high risk of transfusion-associated adverse events such
as transfusion-associated circulatory overload (TACO), transfusion-related lung injury (TRALI), transfusion-related
immunomodulation (TRIM), and anaphylaxis/allergic reactions. Therefore, the avoidance of inappropriate plasma
transfusion bears a high potential of improving patient outcomes. The prospective study by Durila et al., published
recently in BMC Anesthesiology, provides evidence that tracheostomies can be performed without prophylactic
plasma transfusion and bleeding complications in critically ill patients despite increased INR in case of normal
thromboelastometry (ROTEM) results. Thromboelastometry-based restrictive transfusion management helped avoid
unnecessary plasma and platelet transfusion, and should reduce the incidence of transfusion-related adverse events
and transfusion-associated hospital costs. Therefore, the authors believe that thromboelastometry-based strategies
should be implemented to optimize patient blood management in perioperative medicine.
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Background
Thirty to Ninety percent of plasma transfused periopera-
tive or at the ICU has to be considered as inappropriate
[1–6]. Here, plasma transfusion has been considered as in-
appropriate in patients with normal INR (<1.5), transfused
as a prophylaxis in non-bleeding patients with mildly ab-
normal coagulation tests, and transfused in an ineffective
dose (<10 mL/kg bw). Post-transfusion corrections of INR
are consistently small unless the pre-transfusion INR is
only mildly deranged (<2.5) [7]. Notably, the most fre-
quent transfused dose of FFP is two to four units, which
has been shown to be ineffective to improve coagulation
in several studies [6–10]. A systematic review of the litera-
ture including 80 RCTs showed no consistent evidence of
significant benefit for prophylactic and therapeutic use of
FFP across a range of indications evaluated [11]. Accord-
ingly, Müller et al. [12] could not show any differences in
bleeding complications in critically ill patients undergoing
an invasive procedure in their RCT, regardless whether
FFP was prophylactically administered or not. In trauma,
even with a :PRBC transfusion ratio of 1:1 it took in mean
14.8 h to correct an INR of 1.8 ad admission to a INR of <
1.5 at the ICU [13].
On the other hand, plasma transfusion is associated with
a high risk of transfusion-associated adverse events such
as transfusion-associated circulatory overload (TACO),
transfusion-related lung injury (TRALI), transfusion-
related immunomodulation (TRIM), and anaphylaxis/
allergic reactions. TRIM results in a significant increase in
the incidence of nosocomial infections and sepsis in critic-
ally ill surgical patients transfused with FFP (RR, 2.99;
95 % CI, 2.28–3.93) [14]. Still, TRALI is the leading cause
of transfusion-related death in the US with an incidence of
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TRALI/possible TRALI of 1.4 to 3.0 % of adult patients
undergoing surgery and receiving transfusion [15]. Fur-
thermore, TACO is a leading cause of transfusion-related
fatalities in the US with an incidence of 3–5.5 % in trans-
fused patients [16]. This is in line with the SHOT report
2013, reporting TACO as the leading cause of transfusion-
related death (12 of 22 or 54.5 %) and major morbidity (43
of 143 or 30.1 %) in the UK [17]. Accordingly, plasma is
the allogeneic blood product with the highest impact on
increased long-term mortality (HR, 1.060 per unit trans-
fused; P < 0.001) in patients undergoing coronary artery
bypass surgery [18]. Furthermore, in non-massively trans-
fused trauma patients (<10 U PRBC within 12 h of ad-
mission), plasma administration was associated with a
substantial increase in complications, in particular ARDS
(12-fold), with no improvement in survival. An increase in
multiple organ dysfunction (6-fold), pneumonia (4-fold),
and sepsis (4-fold) was likewise seen as increasing volumes
of plasma (>6 U) were transfused [19]. In another US
trauma study, exposure to ABO-compatible (pre-thawed
“universal donor” plasma) versus ABO-identical plasma
resulted in an increase in overall complications (53.5 % vs
40.5 %, P = 0.002), in particular ARDS (19.4 % vs 9.2 %,
P = 0.0011) and sepsis (38.0 % vs 28.9 %, P = 0.02). There
was a stepwise increase in the complication rate as expos-
ure increases (reaching 70.0 % for patients receiving more
than 6 U; these patients also had a 4-fold increase in
ARDS) [20]. This is in line with a study in 86,082 Swedish
patents receiving their first plasma transfusion and had a
follow up of 14 days. Here, transfusion of five or more
units of AB0-compatible but non-identical plasma was as-
sociated with an increased mortality (RR, 1.15; 95 % CI,
1.02–1.29) compared to recipients of only AB0-identical
plasma [21]. Therefore, the avoidance of inappropriate
plasma transfusion has a high potential of improving pa-
tient outcomes.
Main text
Durila et al. [22] assessed in their prospective study, pub-
lished recently in BMC Anesthesiology, whether tracheos-
tomy in 119 septic and non-septic ICU patients can be
performed without bleeding complications in case of nor-
mal thromboelastometry (ROTEM) results (EXTEM CT
(coagulation time)) despite increased INR. Normal INR
(≤1.2) was found in 64 (54 %) patients, while increased
INR (>1.2) was found in 55 (46 %) patients. Patients with
INR ≥ 1.3 (median INR, 1.48; range, 1.3–1.84) were further
assessed by thromboelastometry. Despite prolonged INR,
thromboelastometry results were in normal ranges in
all cases except one. With normal thromboelastometry,
tracheostomy was performed safely without FFP transfu-
sion and any bleeding complication. Here, thromboelasto-
metry analysis avoided unnecessary FFP transfusion in
98 % (54/55) critically ill patients with increased INR.
Since their former practice was to transfuse four units of
FFP prophylactically prior to tracheostomy in patients with
an INR > 1.2, implementation of thromboelastometry test-
ing reduced FFP transfusion from 220 to 4 units in this
setting without any increase in bleeding complications.
Their study provides a valuable contribution to the in-
creasing evidence that invasive interventions, such as
tracheostomy, central venous line insertion or liver biopsy,
can be performed without prophylactic FFP or platelet
transfusion in critically ill patients with abnormal standard
laboratory tests, such as INR or platelet count, in case
of normal thromboelastometry results. This viscoelastic
method can help physicians to avoid unnecessary transfu-
sion and corresponding transfusion-related adverse events.
Discussion
Standard laboratory coagulation tests (SLTs), such as
PT/INR and platelet count, are still frequently used to
assess coagulopathy and to guide hemostatic interven-
tions. However, Haas et al. recently reviewed the evi-
dence for the usefulness of SLTs to assess coagulopathy
and to guide bleeding management in the perioperative
and massive bleeding setting. Evidence for the usefulness
of SLTs was found in only three prospective trials, inves-
tigating a total of 108 patients, whereby microvascular
bleeding was a rare finding. No data from RCTs sup-
ported the use of SLTs. In contrast, numerous investiga-
tions have challenged the reliability of SLTs to assess
coagulopathy or guide bleeding management [23]. In an-
other study, Haas et al. [24] demonstrated that PT/INR
and aPTT tests overestimate the underlying coagulation
factor deficiency if more than one factor is reduced,
which typically occurs in dilutional coagulopathy. Thus,
impaired PT/INR and aPTT values are a very common
and early finding during hemodilution and intraoperative
bleeding, and therefore, decision-making based on PT/
INR and aPTT may lead to considerable over-transfusion
of FFP and other blood products. Nevertheless, increased
INR values correlate quite well with EXTEM CT in
warfarin-treated patients and healthy controls (Spearman
rho = 0.87). Here, EXTEM CT has a sensitivity and specifi-
city of 0.89 and 1.00, respectively, to detect elevated INR
above 1.2, with a positive and negative predictive value of
1.00 and 0.88, respectively [25]. However, the correlation
between INR and EXTEM CT seem to be different in
other setting, such as dilutional coagulopathy, cirrhosis,
sepsis, and patients with extracorporeal assist devices
[24, 26–28]. Here, tissue factor-expression on circulating
monocytes can result in a shortening of CT in whole
blood viscoelastic tests whereas plasmatic SLTs are unable
to detect this effect [29]. In contrast to EXTEM CT, the
false-negative rate of kaolin-TEG and rapid-TEG (kaolin
plus tissue factor activation) for detecting warfarin coagu-
lopathy with either test is clinically unacceptable [30]. This
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may be due to the fact that the intrinsic pathway is acti-
vated in these tests.
Similar considerations have been made regarding the
predictive value of platelet count versus thromboelasto-
metric clot firmness for bleeding after invasive interven-
tions. Weigand et al. [31] demonstrated that coagulation
disorders with altered INR (≥1.5) or platelet count
(≤50×109/L) did not increase the risk of significant
bleeding when inserting a central venous catheter. Zeidler
et al. [32] demonstrated in their retrospective single-
center analysis of 604 central venous catheter insertions in
193 patients with acute leukemia that only patients with
platelet counts of less than 20×109/L were at higher risk of
bleeding compared to patients with platelet counts of
100×109/L or more. However, Greene et al. [33] demon-
strated that thromboelastometric clot firmness (EXTEM
or INTEM A10 or MCF) is superior to platelet count in
predicting bleeding in pediatric patients with immune
thrombocytopenia (ITP) and severe thrombocytopenia
(<30×109/L). Superiority of thromboelastometry max-
imum clot firmness (MCF) compared to platelet count in
predicting bleeding in patients with hematological malig-
nancies has recently been confirmed in the prospective
observational ATHENA study [34]. Further studies con-
firmed that EXTEM clot firmness (A10 and MCF) can be
used to assess the efficacy of prophylactic platelet transfu-
sion before insertion of a central venous catheter in pa-
tients with bone morrow failure and in thrombocytopenic
children undergoing chemotherapy [35, 36]. Furthermore,
Fayed et al. [37] reported that a thromboelastometry-
guided transfusion protocol in patients undergoing liver
transplantation can avoid 75 % of platelet transfusions in
patients with a platelet count < 50×109/L without in-
creased bleeding rate. Therefore, thromboelastometry clot
firmness (EXTEM or INTEM A10 or MCF) should be
considered in addition to EXTEM CT in particular in
critically ill patients with thrombocytopenia undergoing
tracheostomy. However, drug-, trauma- or sepsis-induced
changes in platelet function cannot be detected by stand-
ard viscoelastic tests, such as ROTEM or TEG. This is an
important limitation of viscoelastic testing since the high
amounts of thrombin generated in these test systems can
overwhelm the inhibition of other platelet activation path-
ways, such as the arachidonic acid, collagen, serotonin, or
ADP pathway. This diagnostic gap can be closed by point-
of-care platelet function testing such as whole blood im-
pedance aggregometry (Multiplate or ROTEM platelet)
which is much more sensitive to these effects [28, 38–40].
Platelet dysfunction cannot only be induced by so call
“antiplatelet drugs” but also by a lot of other drugs used
for treatment in critically ill patients such as non-steroidal
anti-inflammatory drugs (NSAIDs), selective serotonin
release inhibitors (SSRIs), β-lactam antibiotics, as well
as cardiovascular and lipid-lowering drugs [41, 42]. In
particular combination of these drugs can induce severe
platelet dysfunction [42, 43].
Accordingly, point-of-care-guided bleeding manage-
ment algorithms, using thromboelastometry and imped-
ance aggregometry, have been shown to be effective in
reducing transfusion requirements in cardiovascular sur-
gery, liver transplantation, trauma, obstetrics, and other
critically ill patients [44–48]. Here, transfusion require-
ments for FFP, PRBC, and platelets could be reduced by
70–90 %, 10–60 %, and 20–70 %, respectively [49]. In
addition, this is associated with significant cost-savings
[48–51]. Furthermore, the incidence of massive transfu-
sion, revision surgery, TACO, acute lung injury, multiple
organ failure, nosocomial infection and sepsis, as well as
thromboembolic events could be reduced significantly
[44, 47–53]. The later can be explained by the high pre-
dictive value of thromboelastometry for postoperative
complications after major non-cardiac surgery (ROC
AUC = 0.751 for INTEM A10), which allows for defining
a therapeutic window to stop bleeding without increased
risk of thromboembolic events [54]. Similar results have
been reported for cardiovascular patients [55].
Conclusions
The prospective study by Durila et al. [22] provides further
evidence that invasive interventions such as tracheostomy
can be performed without prophylactic plasma transfusion
and bleeding complications in critically ill patients with in-
creased INR in case of normal thromboelastometry results.
thromboelastometry-based restrictive transfusion manage-
ment, avoiding unnecessary plasma and platelet trans-
fusion, can reduce the incidence of transfusion-related
adverse events and transfusion-associated hospital costs.
Therefore, the authors believe that thromboelastometry-
based strategies should be implemented to optimize pa-
tient blood management in perioperative medicine.
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